KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $798.4 million.

  • Biomarin Pharmaceutical's Total Current Liabilities rose 1156.7% to $798.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $798.4 million, marking a year-over-year increase of 1156.7%. This contributed to the annual value of $607.0 million for FY2024, which is 4843.03% down from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Total Current Liabilities stood at $798.4 million, which was up 1156.7% from $684.2 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Total Current Liabilities registered a high of $1.2 billion during Q4 2023, and its lowest value of $430.0 million during Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $598.2 million (2023), whereas its average is $690.8 million.
  • In the last 5 years, Biomarin Pharmaceutical's Total Current Liabilities skyrocketed by 12325.88% in 2023 and then tumbled by 4843.03% in 2024.
  • Biomarin Pharmaceutical's Total Current Liabilities (Quarter) stood at $546.5 million in 2021, then rose by 7.76% to $588.9 million in 2022, then surged by 99.87% to $1.2 billion in 2023, then plummeted by 48.43% to $607.0 million in 2024, then surged by 31.54% to $798.4 million in 2025.
  • Its last three reported values are $798.4 million in Q3 2025, $684.2 million for Q2 2025, and $628.2 million during Q1 2025.